Volume 34, No 7, Jul 2024

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 34 Issue 7, July 2024: 475-476

RESEARCH HIGHLIGHTS

Metabolic engineering of the paclitaxel anticancer drug

Audrey Oudin¹ , Nicolas Papon² , Vincent Courdavault^1,*

¹Biomolécules et Biotechnologies Végétales, BBV, EA2106, Université de Tours, Tours, France
²Univ Angers, Univ Brest, IRF, SFR ICAT, F-49000 Angers, France
Correspondence: Vincent Courdavault(vincent.courdavault@univ-tours.fr)

In a recently published Science article, Jiang et al. unraveled a couple of missing enzymes achieving key steps in the paclitaxel biosynthetic pathway in yew and reconstituted the production of the main precursor baccatin III in a heterologous host. This advance provides unprecedented perspectives for biotechnological production of this prominent anticancer drug.

https://doi.org/10.1038/s41422-024-00950-3

FULL TEXT | PDF

Browse 138